# EDGAR Filing Document

**Accession Number:** 0000049071
**File Stem:** 0000049071-25-000061
**Filing Date:** 2025-12
**Character Count:** 16279
**Document Hash:** ebdea1ef219026fc172f45a492351e6c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000049071-25-000061.hdr.sgml**: 20251216

**ACCESSION NUMBER**: 0000049071-25-000061

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251216

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251216

**DATE AS OF CHANGE**: 20251216

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HUMANA INC
- **CENTRAL INDEX KEY:** 0000049071
- **STANDARD INDUSTRIAL CLASSIFICATION:** HOSPITAL & MEDICAL SERVICE PLANS [6324]
- **ORGANIZATION NAME:** 02 Finance
- **EIN:** 610647538
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-05975
- **FILM NUMBER:** 251573389

**BUSINESS ADDRESS:**
- **STREET 1:** 500 W MAIN ST
- **CITY:** LOUISVILLE
- **STATE:** KY
- **ZIP:** 40202
- **BUSINESS PHONE:** 5025801000

**MAIL ADDRESS:**
- **STREET 1:** 500 W. MAIN ST
- **CITY:** LOUISVILLE
- **STATE:** KY
- **ZIP:** 40202

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** EXTENDICARE INC
- **DATE OF NAME CHANGE:** 19740404

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HERITAGE HOUSE OF AMERICA INC
- **DATE OF NAME CHANGE:** 19671129

?xml version='1.0' encoding='ASCII'? hum-20251216

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of** 

**The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): December 16, 2025 (December 16, 2025)**

**Humana Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-5975** | **61-0647538** |
| **(State or other jurisdiction of incorporation)** | **(Commission File Number)** | **(IRS Employer Identification No.)** |

---

**500 West Main Street, Louisville, Kentucky 40202**

**(Address of principal executive offices, including zip code)**

**(502) 580-1000**

**(Registrant's telephone number, including area code)**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **<u>Title of each class</u>** | **<u>Trading Symbol</u>** | **<u>Name of each exchange on which registered</u>** |
| Common Stock | HUM | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

**(b) and (e)**

On December 16, 2025, Humana Inc. (the "Company") announced that after a successful 29-year career at the Company, George Renaudin, Insurance Segment President and member of the Company's Enterprise Leadership Team, will retire by the third quarter of 2026 (the "Transition Date"). Mr. Renaudin has agreed to serve in an advisory capacity to the Company after his transition date.

In connection with his advisory service, Mr. Renaudin entered into an agreement with the Company (the "Agreement"), the material terms of which are summarized below. The payments and benefits to which Mr. Renaudin is entitled under the Agreement are generally subject to his compliance with the terms and conditions of the Agreement.

Pursuant to the terms of the Agreement, Mr. Renaudin agreed to continue to provide strategic advisory services after the Transition Date until December 31, 2026, and thereafter transition to the Company's variable staffing pool ("VSP") (temporary worker status) until March 1, 2027 (the "VSP Period"). While serving as a strategic advisor, Mr. Renaudin will continue to receive his current base salary, annual incentive plan opportunity and benefits, as the same may be adjusted from time to time. During the VSP Period, Mr. Renaudin will not receive a salary, but will be paid an hourly rate for any work performed for the Company, including: (i) continuing to serve on the boards of various joint venture and minority investment companies in the Company's investment portfolio, (ii) advising the Company's business teams as requested regarding ongoing operational and regulatory matters, including participating in public policy matters, and (iii) serving as a strategic consultant to the Company to assist in the transition.

Under the Agreement, Mr. Renaudin will not receive any additional compensation or benefits, other than continued vesting of equity in accordance with applicable provisions under the Company's stock incentive plan, and other existing compensation and benefits programs generally available to the Company's associates, including VSP associates.

At the end of the VSP Period, Mr. Renaudin will receive, subject to his execution of a general release of claims and compliance with applicable non-compete and non-solicit covenants, benefits pursuant to Section 3 of the Company's Executive Severance Policy.

On December 16, 2025, the Company also announced that Aaron Martin will join the Company in January 2026 as President of Medicare Advantage and a member of the Enterprise Leadership Team. Following Mr. Renaudin's Transition Date, Mr. Martin will assume the role of Insurance Segment President, and John Barger, who currently serves as the President of the Company's Medicaid and Dual Eligible programs, will be promoted to the role of President of Medicare Advantage. See the attached press release for additional biographical information concerning Messrs. Martin and Barger.

The foregoing summary of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of each of which is expected to be filed as an exhibit to the Company's Annual Report on Form 10-K for the period ending December 31, 2025.

------

**Item 7.01. Regulation FD Disclosure.**

The Company reaffirms its guidance of approximately $12.26 in diluted earnings per common share ("EPS") or approximately $17.00 in adjusted earnings per common share ("Adjusted EPS"), in each case for the year ending December 31, 2025 ("FY 2025"). This guidance is consistent with the guidance issued in the Company's press release dated November 5, 2025 and Form 8-K filed on December 1, 2025.

The Company has included Adjusted EPS in this current report, a financial measure that is not in accordance with Generally Accepted Accounting Principles ("GAAP"). Management believes that this measure, when presented in conjunction with the comparable measure of GAAP EPS, provides a comprehensive perspective to more accurately compare and analyze the Company's core operating performance over time. Consequently, management uses Adjusted EPS as a consistent and uniform indicator of the Company's core business operations from period to period, as well as for planning and decision-making purposes and in determination of incentive compensation. Adjusted EPS should be considered in addition to, but not as a substitute for, or superior to, GAAP EPS. A reconciliation of GAAP EPS to Adjusted EPS follows:

---

| | |
|:---|:---|
| **Diluted earnings per common share** | **FY 2025 Guidance** |
| **GAAP** | **approximately** **$12.26** |
| Amortization of identifiable intangibles | 0.42 |
| Put/call valuation adjustments associated with the Company's non-consolidating minority interest investments (a) | 3.81 |
| Value creation initiatives (a) | 2.65 |
| Impact of exit of employer group commercial products business (a) | (0.52) |
| Settlement of certain litigation expenses (a) | 0.13 |
| Loss on sale of business (a) | 0.52 |
| Impairment charges (a) | 0.27 |
| Cumulative net tax impact | (2.54) |
| **Adjusted (non-GAAP) – FY 2025 projected (a)** | **approximately** **$17.00** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) FY 2025 GAAP EPS guidance and FY 2025 Adjusted (non-GAAP) EPS guidance exclude the impact of future value changes to items that have not yet been recognized or cannot be reasonably estimated at this time. The Company does not expect changes to its FY 2025 Adjusted (non-GAAP) EPS guidance. The Company does expect potential changes to its FY 2025 GAAP EPS guidance due to its ongoing value creation and other strategic initiatives.

**<u>Cautionary Statement</u>**

This Current Report on Form 8-K includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, generally including the words or phrases like "expects," "believes," "anticipates," "intends," "likely will result," "estimates," "projects" or variations of such words and similar expressions that are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and assumptions, including, among other things, information set forth in the "Risk Factors" section of the Company's SEC filings.

------

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits:

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**<u>Exhibit No.</u>** | **<u>Description</u>** |
| [99.1](exhibit991newsrelease.htm) | [Press Release](exhibit991newsrelease.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **HUMANA INC.** | **HUMANA INC.** |
| **BY:** | **/s/ Joseph C. Ventura** |
| | **Joseph C. Ventura** |
| | **Chief Legal Officer** |

---

Dated: December 16, 2025

## Exhibit 99.1

**n e w s** r e l e a s e

**Exhibit 99.1**

---

| | |
|:---|:---|
| &nbsp;&nbsp;**FOR MORE INFORMATION, CONTACT:** | &nbsp;&nbsp;**FOR MORE INFORMATION, CONTACT:** |
| &nbsp;&nbsp;Lisa Stoner<br>Humana Investor Relations<br>(502) 580-2652<br>e-mail: lstamper@humana.com | ![humanalogoa.jpg](humanalogoa.jpg) |
|  | ![humanalogoa.jpg](humanalogoa.jpg) |
| &nbsp;&nbsp;Mark Taylor<br>Humana Corporate Communications<br>(317) 753-0345<br>e-mail: mtaylor108@humana.com | ![humanalogoa.jpg](humanalogoa.jpg) |

---

**Humana Announces Insurance Leadership Transition**

*George Renaudin to Retire as Insurance Segment President by Q3 2026*

*Aaron Martin to Join as President of Medicare Advantage and Insurance Segment President Successor John Barger to Succeed Martin as President of Medicare Advantage* 

**LOUISVILLE, Ky.** — December 16, 2025 — Humana Inc. (NYSE: HUM) today announced that George Renaudin, Insurance Segment President and member of Humana's Enterprise Leadership Team, will retire by Q3 2026 following a successful 29-year career at the company. During this period, Renaudin played a pivotal role in establishing and growing Humana's Medicare Advantage and Medicaid programs, helping to build them into high-performing businesses and assembling a strong insurance leadership team.

"George has contributed greatly to Humana's success, driving the growth of these programs, and shaping our value-based care strategy," said Humana President and CEO Jim Rechtin. "He has been instrumental in positioning us for long-term success, with sustained membership growth and consistent high-quality care. We are grateful for his commitment to a smooth transition that ensures continuity for our people, partners and upcoming priorities, including next year's annual bid process."

"I am deeply proud of the work we've done in my nearly three decades at Humana, and after much thought and planning, I am confident that this is the right time for me to announce my retirement," said Renaudin. "We have built a strong team across our Medicare Advantage, Medicaid, and Specialty businesses, making them well positioned to deliver on our strategy while driving value for years to come."

Humana also announced that Aaron Martin will join the company in January 2026 as President of Medicare Advantage and a member of the Enterprise Leadership Team. The newly created role will report jointly to Renaudin and Rechtin and consolidate Humana's Medicare Advantage operations under a single leader to drive operational excellence across the businesses. Following Renaudin's retirement, Martin will assume the role of Insurance Segment President and John Barger will be promoted to the role of President of Medicare Advantage, reporting directly to Martin. Barger is currently President of Humana's Medicaid and Dual Eligible programs and has more than 25 years of experience serving in critical roles at the company, including more than a decade supporting the Medicare Advantage business. After retiring, Renaudin will serve as a strategic advisor to the company through at least the end of 2026 to ensure a thoughtful transition.

Page 1 of 2

------

**n e w s** r e l e a s e

"We are incredibly excited to welcome Aaron to Humana. His experience in applying technology and a consumer-centric approach within the healthcare ecosystem will strengthen our ability to serve members and deliver better outcomes," said Rechtin. "Aaron's proven ability to lead healthcare organizations through periods of transformation will position him to provide immediate and impactful oversight of our talented and experienced insurance team. At the same time, we are also pleased that a seasoned and disciplined Humana leader such as John will ultimately be leading our Medicare Advantage business. We are confident that with these appointments, our insurance team will continue to advance our efforts to become a worldclass, consumer healthcare company and position Humana for continued shareholder value creation."

Martin was Vice President of Healthcare at Amazon, where he oversaw strategic partnerships, marketing and the company's telehealth and chronic conditions programs. There, he focused on making healthcare more convenient, engaging and valuable to customers. Prior to Amazon, he was Executive Vice President and Chief Digital Officer for Providence, a comprehensive not-for-profit health system serving 8 states, and Managing General Partner for Providence Ventures. Martin joined Providence after a previous career with Amazon. He holds Bachelor of Arts degrees from Austin College and earned an MBA from Wharton at the University of Pennsylvania.

**<u>About Humana</u>**

Humana is a leading U.S. healthcare company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.

\# \# \#

Page 2 of 2